Dexmedetomidine-13C,d3 hydrochloride(Synonyms: (+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Dexmedetomidine-13C,d3 hydrochloride (Synonyms: (+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride)

Dexmedetomidine-13C,d3 (hydrochloride) 是一种 13C- 和氘代标记的 Dexmedetomidine (hydrochloride)。Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) 是一种有效，选择性和具有口服活性的 α2 肾上腺素能受体 (α2-adrenoceptor) 激动剂，Ki 值为 1.08 nM。Dexmedetomidine hydrochloride 对 α1 肾上腺素受体显示出 1620 倍的选择性。Dexmedetomidine hydrochloride 具有抗焦虑作用，可用于促进安定和缓解疼痛的研究。

Dexmedetomidine-13C,d3 hydrochloride(Synonyms: (+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride)

Dexmedetomidine-13C,d3 hydrochloride Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Dexmedetomidine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled. Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects[1][2][3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[78].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

240.75

Formula

C1213CH14D3ClN2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.

    [2]. Virtanen R, et, al. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1988 May 20;150(1-2):9-14.

    [3]. Gertler R, et, al. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001 Jan;14(1):13-21.

    [4]. Sajid B, et, al. A comparison of oral dexmedetomidine and oral midazolam as premedicants in children. J Anaesthesiol Clin Pharmacol. Jan-Mar 2019;35(1):36-40.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务